Goldman Sachs’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,706,600
| Closed | -$116M | – | 6645 |
|
|
2022
Q3 | $116M | Buy |
1,706,600
+1,033,433
| +154% | +$57M | 0.03% | 611 |
|
|
2022
Q2 | $21.5M | Sell |
673,167
-1,160,553
| -63% | -$34M | 0.01% | 1839 |
|
|
2022
Q1 | $63.5M | Buy |
1,833,720
+595,983
| +48% | +$17.8M | 0.01% | 1091 |
|
|
2021
Q4 | $36.2M | Buy |
1,237,737
+461,580
| +59% | +$14.3M | 0.01% | 1610 |
|
|
2021
Q3 | $19.8M | Buy |
776,157
+110,167
| +17% | +$3.24M | ﹤0.01% | 2071 |
|
|
2021
Q2 | $23.3M | Buy |
665,990
+195,041
| +41% | +$7.61M | 0.01% | 1914 |
|
|
2021
Q1 | $19.2M | Sell |
470,949
-428,699
| -48% | -$19.7M | ﹤0.01% | 1964 |
|
|
2020
Q4 | $39M | Buy |
899,648
+329,330
| +58% | +$16.2M | 0.01% | 1317 |
|
|
2020
Q3 | $31.4M | Sell |
570,318
-43,336
| -7% | -$2.75M | 0.01% | 1377 |
|
|
2020
Q2 | $38.7M | Sell |
613,654
-84,603
| -12% | -$5.8M | 0.01% | 1172 |
|
|
2020
Q1 | $35.7M | Buy |
698,257
+148,545
| +27% | +$9.95M | 0.01% | 1094 |
|
|
2019
Q4 | $43.7M | Buy |
549,712
+131,126
| +31% | +$7.77M | 0.01% | 1246 |
|
|
2019
Q3 | $20.3M | Sell |
418,586
-139,226
| -25% | -$7.26M | 0.01% | 1763 |
|
|
2019
Q2 | $29.3M | Buy |
557,812
+42,536
| +8% | +$2.44M | 0.01% | 1557 |
|
|
2019
Q1 | $27.3M | Buy |
515,276
+86,374
| +20% | +$4.24M | 0.01% | 1603 |
|
|
2018
Q4 | $17.6M | Buy |
428,902
+4,224
| +1% | +$158K | 0.01% | 1908 |
|
|
2018
Q3 | $16.1M | Sell |
424,678
-547
| -0.1% | -$24.2K | ﹤0.01% | 2084 |
|
|
2018
Q2 | $19.2M | Buy |
425,225
+22,153
| +5% | +$1.01M | 0.01% | 1901 |
|
|
2018
Q1 | $19.5M | Buy |
403,072
+129,737
| +47% | +$7.24M | 0.01% | 1880 |
|
|
2017
Q4 | $10.8M | Sell |
273,335
-2,282
| -0.8% | -$85.2K | ﹤0.01% | 2409 |
|
|
2017
Q3 | $8.56M | Sell |
275,617
-41,954
| -13% | -$1.18M | ﹤0.01% | 2695 |
|
|
2017
Q2 | $8.69M | Buy |
317,571
+215,690
| +212% | +$6.42M | ﹤0.01% | 2617 |
|
|
2017
Q1 | $3.75M | Buy |
101,881
+62,231
| +157% | +$1.57M | ﹤0.01% | 3178 |
|
|
2016
Q4 | $573K | Buy |
+39,650
| New | +$697K | ﹤0.01% | 4929 |
|
|
2016
Q3 | – | Sell |
-68,529
| Closed | -$1.14M | – | 7247 |
|
|
2016
Q2 | $1.14M | Sell |
68,529
-60,330
| -47% | -$1.22M | ﹤0.01% | 4083 |
|
|
2016
Q1 | $2.04M | Buy |
128,859
+104,139
| +421% | +$1.85M | ﹤0.01% | 3445 |
|
|
2015
Q4 | $799K | Buy |
24,720
+18,721
| +312% | +$811K | ﹤0.01% | 4509 |
|
|
2015
Q3 | $253K | Buy |
+5,999
| New | +$283K | ﹤0.01% | 5771 |
|
Other funds holding GBT
Goldman Sachs's GBT Position: Q4 2022 in Review
Goldman Sachs sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,706,600 shares — an estimated $116M sold.
Goldman Sachs first reported a position in GBT in Q3 2015 and held it in 28 quarters. The position peaked at $116M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Goldman Sachs reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Goldman Sachs sold 1,706,600 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $116M.
- Goldman Sachs first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 28 quarters.
- Goldman Sachs's Global Blood Therapeutics, Inc. position peaked at $116M in Q3 2022.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.